Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

Carlos Escobar CervantesJulio Martí-AlmorAlejandro Isidoro Pérez CabezaKevin BowrinAleix Llorac MoixMar Genís GironèsDavid GascheAurélie MillierJean TarduMondher ToumiJean-Baptiste Brière

Published in: PloS one (2022)

These results suggest that rivaroxaban and dabigatran are cost-effective versus vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation, from the Spanish National Health System perspective.

Keyphrases

atrial fibrillation
oral anticoagulants
catheter ablation
left atrial
left atrial appendage
direct oral anticoagulants
heart failure
percutaneous coronary intervention
venous thromboembolism